chromosomal microarray (CMA)
Chromosomal microarray (CMA) is recommended as a first-tier testing strategy among individuals presenting with developmental delay, intellectual impairment, autism spectrum, and multiple congenital anomalies. In this targeted population, karyotyping is appropriate for first-line testing in patients with features consistent with a specific chromosomal abnormality (e.g., Down syndrome).
Targeted molecular genetic testing is appropriate for conditions like fragile X syndrome that are not detected by CMA. Specific findings that may point a clinician toward looking for a specific syndrome and thus be less inclined to order CMA testing include:
- Characteristic physical features
- Specific constellations of congenital malformations
- Certain cognitive/developmental profiles
- Clear pattern of inheritance in the family
References:
Batzir NA, Shohat M, Maya I. Chromosomal microarray analysis (CMA): a clinical diagnostic tool in the prenatal and postnatal settings. Pediatr Endocrinol Rev. 2015;13(1):448-454.
Kharbanda M, Tolmie J, Joss S. How to use… microarray comparative genomic hybridisation to investigate developmental disorders. Arch Dis Child Educ Pract Ed. 2015;100(1):24-29.